Which GLP-1 and SGLT2 Drugs Best Protect Heart and Kidneys in Type 2 Diabetes?
A network meta-analysis of 14 major trials found that sotagliflozin was best for reducing heart attacks, strokes, and heart failure hospitalizations, while semaglutide and empagliflozin led for lowering death risk in type 2 diabetes patients.
Quick Facts
What This Study Found
Sotagliflozin ranked first for MACE (HR 0.76), heart failure hospitalization (HR 0.59), MI (HR 0.65), and stroke (HR 0.56). Empagliflozin and dapagliflozin led for kidney protection. Oral semaglutide and empagliflozin were best for all-cause death reduction.
Key Numbers
14 CVOTs; sotagliflozin MACE HR 0.76; HHF HR 0.59; MI HR 0.65; stroke HR 0.56; oral semaglutide and empagliflozin best for all-cause death
How They Did This
Bayesian network meta-analysis of 14 cardiovascular or renal outcome trials (CVOTs) from PubMed and Embase. Endpoints: MACE, stroke, MI, cardiovascular death, all-cause death, kidney function progression, and heart failure hospitalization. Hazard ratios with 95% CI and SUCRA rankings calculated.
Why This Research Matters
Not all GLP-1 and SGLT2 drugs are equal for heart and kidney protection. This analysis gives clinicians evidence to match specific drugs to each patient's most important cardiovascular or renal risks.
The Bigger Picture
As GLP-1 and SGLT2 drugs become standard diabetes care, understanding which specific drug best addresses each patient's risk profile enables precision medicine. This analysis supports a shift from class-level to drug-specific prescribing decisions.
What This Study Doesn't Tell Us
Network meta-analysis uses indirect comparisons between trials with different patient populations, follow-up durations, and baseline risks. Some drug-to-drug comparisons had wide confidence intervals. Sotagliflozin trials included heart failure patients, potentially inflating its cardiovascular benefit.
Questions This Raises
- ?Would combining the best SGLT2 inhibitor with the best GLP-1 RA provide additive cardiorenal protection?
- ?Do the rankings change in patients without established cardiovascular disease?
- ?Why did ertugliflozin underperform compared to other SGLT2 inhibitors?
Trust & Context
- Key Stat:
- HR 0.59 for heart failure Sotagliflozin reduced heart failure hospitalization by 41% compared to the reference drug, ranking first among all 12 drugs analyzed
- Evidence Grade:
- High evidence grade: network meta-analysis of 14 randomized cardiovascular/renal outcome trials, though indirect comparisons introduce some uncertainty.
- Study Age:
- Published in 2021. Additional cardiovascular outcome trials for GLP-1 and SGLT2 drugs have reported since, which may refine these rankings.
- Original Title:
- Comparative efficacy of 5 sodium glucose cotransporter 2 inhibitor and 7 glucagon-like peptide 1 receptor agonists interventions on cardiorenal outcomes in type 2 diabetes patients: A network meta-analysis based on cardiovascular or renal outcome trials.
- Published In:
- Medicine, 100(30), e26431 (2021)
- Authors:
- Duan, Xue-Yan, Liu, Shu-Yan, Yin, Dao-Gen
- Database ID:
- RPEP-05354
Evidence Hierarchy
Frequently Asked Questions
Which diabetes drug is best for heart protection?
This meta-analysis found sotagliflozin ranked first for preventing major cardiovascular events, heart attacks, strokes, and heart failure hospitalizations. For reducing death, oral semaglutide and empagliflozin ranked highest.
Are GLP-1 drugs or SGLT2 inhibitors better for kidneys?
SGLT2 inhibitors — specifically dapagliflozin and empagliflozin — ranked highest for slowing kidney disease progression. GLP-1 drugs like semaglutide excelled more on cardiovascular endpoints like stroke and death.
Read More on RethinkPeptides
Cite This Study
https://rethinkpeptides.com/research/RPEP-05354APA
Duan, Xue-Yan; Liu, Shu-Yan; Yin, Dao-Gen. (2021). Comparative efficacy of 5 sodium glucose cotransporter 2 inhibitor and 7 glucagon-like peptide 1 receptor agonists interventions on cardiorenal outcomes in type 2 diabetes patients: A network meta-analysis based on cardiovascular or renal outcome trials.. Medicine, 100(30), e26431. https://doi.org/10.1097/MD.0000000000026431
MLA
Duan, Xue-Yan, et al. "Comparative efficacy of 5 sodium glucose cotransporter 2 inhibitor and 7 glucagon-like peptide 1 receptor agonists interventions on cardiorenal outcomes in type 2 diabetes patients: A network meta-analysis based on cardiovascular or renal outcome trials.." Medicine, 2021. https://doi.org/10.1097/MD.0000000000026431
RethinkPeptides
RethinkPeptides Research Database. "Comparative efficacy of 5 sodium glucose cotransporter 2 inh..." RPEP-05354. Retrieved from https://rethinkpeptides.com/research/duan-2021-comparative-efficacy-of-5
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.